Make Better Decisions

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Obtain formulation and manufacturing information
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Citi
Harvard Business School
Accenture
Baxter
McKesson
Fuji
Deloitte
Express Scripts
QuintilesIMS
UBS

Generated: January 21, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 050141

« Back to Dashboard

NDA 050141 describes BICILLIN L-A, which is a drug marketed by King Pharms Llc and Wyeth Ayerst and is included in two NDAs. It is available from two suppliers. Additional details are available on the BICILLIN L-A profile page.

The generic ingredient in BICILLIN L-A is penicillin g benzathine. There are eighty-nine drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the penicillin g benzathine profile page.
Summary for 050141
Tradename:BICILLIN L-A
Applicant:King Pharms Llc
Ingredient:penicillin g benzathine
Patents:0
Therapeutic Class:Antibacterials
Formulation / Manufacturing:see details
Pharmacology for NDA: 050141
Ingredient-typePenicillins
Medical Subject Heading (MeSH) Categories for 050141
Suppliers and Packaging for NDA: 050141
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
BICILLIN L-A penicillin g benzathine INJECTABLE;INJECTION 050141 NDA A-S Medication Solutions 50090-1016 50090-1016-0 10 SYRINGE in 1 PACKAGE (50090-1016-0) > 2 mL in 1 SYRINGE
BICILLIN L-A penicillin g benzathine INJECTABLE;INJECTION 050141 NDA A-S Medication Solutions 50090-1016 50090-1016-1 1 SYRINGE in 1 PACKAGE (50090-1016-1) > 2 mL in 1 SYRINGE

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:INJECTABLE;INJECTIONStrength600,000 UNITS/ML
Approval Date:Approved Prior to Jan 1, 1982TE:BCRLD:Yes

Profile for product number 003

Active Rx/OTC/Discontinued:RXDosage:INJECTABLE;INJECTIONStrength300,000 UNITS/ML
Approval Date:Approved Prior to Jan 1, 1982TE:RLD:Yes

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Covington
Julphar
QuintilesIMS
Argus Health
AstraZeneca
Colorcon
Novartis
US Department of Justice
Fish and Richardson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot